NYSE:NVS - Novartis Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Novartis AG Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $92.99 -0.07 (-0.08 %) (As of 12/15/2019 04:00 PM ET) Add Compare Today's Range$92.65Now: $92.99▼$93.2550-Day Range$87.08MA: $90.00▼$93.0952-Week Range$72.19Now: $92.99▼$95.00Volume1.37 million shsAverage Volume1.61 million shsMarket Capitalization$213.11 billionP/E Ratio18.27Dividend Yield1.98%Beta0.6 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. Read More… Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:NVS Previous Symbol CUSIPN/A CIK1114448 Webhttp://www.novartis.com/ Phone011-41-61-324-1111Debt Debt-to-Equity Ratio0.42 Current Ratio0.95 Quick Ratio0.73Price-To-Earnings Trailing P/E Ratio18.27 Forward P/E Ratio17.81 P/E Growth2.07 Sales & Book Value Annual Sales$51.90 billion Price / Sales4.11 Cash Flow$8.14 per share Price / Cash Flow11.42 Book Value$34.07 per share Price / Book2.73Profitability EPS (Most Recent Fiscal Year)$5.09 Net Income$12.61 billion Net Margins24.43% Return on Equity20.86% Return on Assets9.31%Miscellaneous Employees125,161 Outstanding Shares2,291,800,000Market Cap$213.11 billion Next Earnings Date1/29/2020 (Estimated) OptionableOptionable Receive NVS News and Ratings via Email Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter. NVS Rates by TradingView Novartis (NYSE:NVS) Frequently Asked Questions What is Novartis' stock symbol? Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS." How often does Novartis pay dividends? What is the dividend yield for Novartis? Novartis announced an annual dividend on Thursday, January 31st. Stockholders of record on Tuesday, March 5th will be given a dividend of $2.8646 per share on Wednesday, March 13th. This represents a dividend yield of 3.27%. The ex-dividend date is Monday, March 4th. This is a boost from Novartis's previous annual dividend of $2.33. View Novartis' Dividend History. How were Novartis' earnings last quarter? Novartis AG (NYSE:NVS) issued its quarterly earnings results on Tuesday, October, 22nd. The company reported $1.41 EPS for the quarter, beating the consensus estimate of $1.31 by $0.10. The company had revenue of $12.17 billion for the quarter, compared to the consensus estimate of $11.67 billion. Novartis had a net margin of 24.43% and a return on equity of 20.86%. The company's revenue was up 10.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.32 EPS. View Novartis' Earnings History. When is Novartis' next earnings date? Novartis is scheduled to release their next quarterly earnings announcement on Wednesday, January 29th 2020. View Earnings Estimates for Novartis. What price target have analysts set for NVS? 9 Wall Street analysts have issued 12 month price objectives for Novartis' shares. Their forecasts range from $79.16 to $105.00. On average, they expect Novartis' share price to reach $91.67 in the next year. This suggests that the stock has a possible downside of 1.4%. View Analyst Price Targets for Novartis. What is the consensus analysts' recommendation for Novartis? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 3 sell ratings, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis. Has Novartis been receiving favorable news coverage? Media stories about NVS stock have been trending neutral this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Novartis earned a news impact score of 0.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Novartis. Are investors shorting Novartis? Novartis saw a increase in short interest in November. As of November 29th, there was short interest totalling 2,900,000 shares, an increase of 10.7% from the November 14th total of 2,620,000 shares. Based on an average trading volume of 1,720,000 shares, the days-to-cover ratio is currently 1.7 days. Currently, 0.1% of the shares of the company are sold short. View Novartis' Current Options Chain. Who are some of Novartis' key competitors? Some companies that are related to Novartis include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AbbVie (ABBV), AstraZeneca (AZN), Sanofi (SNY), Eli Lilly And Co (LLY), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY). What other stocks do shareholders of Novartis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), AbbVie (ABBV), Pfizer (PFE), Cisco Systems (CSCO), AT&T (T), Intel (INTC), NVIDIA (NVDA), Merck & Co., Inc. (MRK) and Verizon Communications (VZ). Who are Novartis' key executives? Novartis' management team includes the folowing people: Dr. Vasant Narasimhan, Chief Exec. Officer (Age 43)Mr. Harry Kirsch, Chief Financial Officer (Age 54)Mr. Steffen Lang, Global Head of Technical Operations (Age 52)Ms. Shannon Thyme Klinger, Group Gen. Counsel (Age 48)Dr. Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer (Age 51) Who are Novartis' major shareholders? Novartis' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.36%), State Street Corp (0.12%), Schafer Cullen Capital Management Inc (0.12%), Parametric Portfolio Associates LLC (0.11%), Manning & Napier Group LLC (0.11%) and Boston Partners (0.08%). Which institutional investors are selling Novartis stock? NVS stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Eagle Asset Management Inc., Schafer Cullen Capital Management Inc, Thomasville National Bank, Carillon Tower Advisers Inc., Manning & Napier Group LLC, Stifel Financial Corp and SG Americas Securities LLC. Which institutional investors are buying Novartis stock? NVS stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Fisher Asset Management LLC, Voloridge Investment Management LLC, Renaissance Group LLC, First Trust Advisors LP, Voya Investment Management LLC, Envestnet Asset Management Inc. and Parametric Portfolio Associates LLC. How do I buy shares of Novartis? Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Novartis' stock price today? One share of NVS stock can currently be purchased for approximately $92.99. How big of a company is Novartis? Novartis has a market capitalization of $213.11 billion and generates $51.90 billion in revenue each year. The company earns $12.61 billion in net income (profit) each year or $5.09 on an earnings per share basis. Novartis employs 125,161 workers across the globe.View Additional Information About Novartis. What is Novartis' official website? The official website for Novartis is http://www.novartis.com/. How can I contact Novartis? Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 011-41-61-324-1111 or via email at [email protected] MarketBeat Community Rating for Novartis (NYSE NVS)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 476 (Vote Outperform)Underperform Votes: 542 (Vote Underperform)Total Votes: 1,018MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/15/2019 by MarketBeat.com StaffFeatured Article: 12b-1 Fees